HBV RNA at 6 months after nucleos(t)ide analogues treatment can predict antiviral efficacy in chronic hepatitis B patients.

ABSTRACT:

Background

This multicenter study evaluated serum HBV RNA as a prognostic biomarker for nucleos(t)ide analogue (NA) therapy in chronic hepatitis B (CHB), focusing on correlations with HBV DNA/HBsAg and predictive value for virological response (VR) and HBeAg seroconversion.

Methods

From 2020 to 2024, 427 treatment-naive HBeAg-positive CHB patients across nine Chinese hospitals were enrolled. Longitudinal HBV RNA-DNA-HBsAg correlations were analyzed during 24-month NA therapy. Predictive performance for VR at 12 months and HBeAg seroconversion at 24 months was assessed.

Results

Non-VR patients had higher baseline HBV DNA (median 7.42 vs. 5.38 log₁₀ IU/mL, P = 0.001) and HBV RNA (6.63 vs. 4.60 log₁₀ copies/mL, P = 0.001). Pretreatment HBV RNA corre

SUBMITTER: Xie Y 

PROVIDER: S-EPMC12857138 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature